Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors
暂无分享,去创建一个
Narasimhan P. Agaram | C. Antonescu | S. Singer | R. Maki | R. DeMatteo | Grace C. Wong | P. Besmer | T. Guo
[1] D. Peeper,et al. BRAFE600 in benign and malignant human tumours , 2008, Oncogene.
[2] T. Pemberton,et al. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. , 2007, Seminars in Oncology.
[3] Electron Kebebew,et al. The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer , 2007, Annals of surgery.
[4] Narasimhan P. Agaram,et al. Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor , 2007, Clinical Cancer Research.
[5] Narasimhan P. Agaram,et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition , 2007, International journal of cancer.
[6] P. Minoo,et al. Role of BRAF‐V600E in the serrated pathway of colorectal tumourigenesis , 2007, The Journal of pathology.
[7] Narasimhan P. Agaram,et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.
[8] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] N. Socci,et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor , 2006, Proceedings of the National Academy of Sciences.
[11] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[12] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[13] P. Pauwels,et al. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall , 2005, Histopathology.
[14] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[15] S. Tripp,et al. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. , 2005, Human pathology.
[16] M. Pierotti,et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma , 2004, Oncogene.
[17] M. van Glabbeke,et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.
[18] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] David J. Wilson,et al. Absence of BRAF and NRAS mutations in uveal melanoma. , 2003, Cancer research.
[20] M. Ladanyi,et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] D. Polsky,et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.
[22] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[23] Richard Wooster,et al. BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.
[24] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[25] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[26] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[27] D. Bonneau,et al. Mutations of the human PTEN gene , 2000, Human mutation.
[28] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[29] Paul Workman,et al. Inhibitors of the HSP90 molecular chaperone: current status. , 2006, Advances in cancer research.